BeiGene Ltd (BGNE) Event July 20, 2022, 21:07 UTC (99% Neutral) BEIGENE, LTD. (BGNE) Announces Regulatory Update Full text
Register to leave comments News bot Oct. 2, 2025, 3:48 p.m. 📋 BEIGENE, LTD. (BGNE) - Regulatory Update Filing Date: 2022-07-20 Accepted: 2022-07-20 17:07:05 Event Type: Regulatory Update Event Details: BeiGene Ltd (BGNE) Announces Regulatory Update BeiGene Ltd (BGNE) provided an update on regulatory developments for its product portfolio. Regulatory Update Details: None Clinical Development: 🔬 Clinical Development Pipeline (BEIGENE, LTD.): Product Type Development Stage Therapeutic Area Source LBL-007 DRUG Phase PHASE1 Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2 ClinicalTrials.gov Tislelizumab DRUG Phase PHASE1 Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2 ClinicalTrials.gov BGB-A425 DRUG Phase PHASE1 Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2 ClinicalTrials.gov Chemotherapy Doublet DRUG Phase PHASE2 Esophageal Cancer ClinicalTrials.gov 5-Fluorouracil DRUG Phase PHASE1 Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer ClinicalTrials.gov Capecitabine DRUG Phase PHASE1 Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer ClinicalTrials.gov Bevacizumab or Bevacizumab biosimilar DRUG Phase PHASE1 Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer ClinicalTrials.gov BG-60366 DRUG Phase PHASE1 Non-Small Cell Lung Cancer ClinicalTrials.gov BGB-15025 DRUG Phase PHASE2 Non-Small Cell Lung Cancer ClinicalTrials.gov Ramucirumab DRUG Phase PHASE2 Non-Small Cell Lung Cancer ClinicalTrials.gov Docetaxel DRUG Phase PHASE2 Non-Small Cell Lung Cancer ClinicalTrials.gov BGB-A445 DRUG Phase PHASE2 Non-Small Cell Lung Cancer ClinicalTrials.gov rituximab DRUG Phase PHASE3 Mantle Cell Lymphoma; Non-Hodgkin Lymphoma ClinicalTrials.gov bendamustine DRUG Phase PHASE3 Mantle Cell Lymphoma; Non-Hodgkin Lymphoma ClinicalTrials.gov zanubrutinib DRUG Phase PHASE3 Mantle Cell Lymphoma; Non-Hodgkin Lymphoma ClinicalTrials.gov Fruquintinib DRUG Phase PHASE2 Minimal Residual Disease ClinicalTrials.gov BGB-16673 DRUG Phase PHASE1 B-cell Malignancy ClinicalTrials.gov Methylprednisolone DRUG Phase PHASE3 Chronic Lymphocytic Leukemia ClinicalTrials.gov Obinutuzumab DRUG Phase PHASE3 CLL ClinicalTrials.gov Venetoclax DRUG Phase PHASE3 CLL ClinicalTrials.gov Sonrotoclax DRUG Phase PHASE3 CLL ClinicalTrials.gov Idelalisib DRUG Phase PHASE3 CLL ClinicalTrials.gov Oxaliplatin DRUG Phase PHASE3 Metastatic Gastric Adenocarcinoma ClinicalTrials.gov 5-fluorouracil (5-FU) DRUG Phase PHASE3 Metastatic Gastric Adenocarcinoma ClinicalTrials.gov Leucovorin DRUG Phase PHASE3 Metastatic Gastric Adenocarcinoma ClinicalTrials.gov Cisplatin DRUG Phase PHASE3 Metastatic Gastric Adenocarcinoma ClinicalTrials.gov Intravenous Tislelizumab DRUG Phase PHASE3 Metastatic Gastric Adenocarcinoma ClinicalTrials.gov Subcutaneous Tislelizumab DRUG Phase PHASE3 Metastatic Gastric Adenocarcinoma ClinicalTrials.gov Placebo DRUG Phase PHASE2 Rheumatoid Arthritis ClinicalTrials.gov BGB-45035 DRUG Phase PHASE2 Rheumatoid Arthritis ClinicalTrials.gov BGB-23339 DRUG Phase PHASE1 Not Determined ClinicalTrials.gov BGB-11417 DRUG Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov Posaconazole DRUG Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov Azacitidine DRUG Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov Glofitamab DRUG Phase PHASE1 B-cell Malignancy ClinicalTrials.gov Mosunetuzumab DRUG Phase PHASE1 B-cell Malignancy ClinicalTrials.gov Lenvatinib DRUG Phase PHASE3 Advanced Malignancies ClinicalTrials.gov Surzebiclimab DRUG Phase PHASE3 Advanced Malignancies ClinicalTrials.gov Zanidatamab DRUG Phase PHASE3 Advanced Malignancies ClinicalTrials.gov BAT1706 DRUG Phase PHASE3 Advanced Malignancies ClinicalTrials.gov Ociperlimab DRUG Phase PHASE3 Advanced Malignancies ClinicalTrials.gov Sitravatinib DRUG Phase PHASE3 Advanced Malignancies ClinicalTrials.gov Temozolomide DRUG Phase PHASE3 Advanced Malignancies ClinicalTrials.gov Pamiparib DRUG Phase PHASE3 Advanced Malignancies ClinicalTrials.gov Chemotherapy DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov BGB-26808 DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov BGB-C354 DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov BG-C9074 DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov BGB-43395 DRUG Phase PHASE1 Hormone-receptor-positive Breast Cancer ClinicalTrials.gov Fulvestrant DRUG Phase PHASE1 Hormone-receptor-positive Breast Cancer ClinicalTrials.gov BGB-21447 DRUG Phase PHASE1 Hormone-receptor-positive Breast Cancer ClinicalTrials.gov BG-68501 DRUG Phase PHASE1 Breast Cancer ClinicalTrials.gov Cetuximab DRUG Phase PHASE1 Metastatic Solid Tumors ClinicalTrials.gov BGB-53038 DRUG Phase PHASE1 Metastatic Solid Tumors ClinicalTrials.gov Lenalidomide DRUG Phase PHASE3 Relapsed/Refractory Follicular Lymphoma ClinicalTrials.gov BG-C477 DRUG Phase PHASE1 Advanced Solid Tumors ClinicalTrials.gov Standard of Care Therapy DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov BG-89894 DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov BGB-58067 DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov BGB-B2033 DRUG Phase PHASE1 Metastatic Hepatocellular Carcinoma ClinicalTrials.gov Nab paclitaxel DRUG Phase PHASE2 Non-small Cell Lung Cancer ClinicalTrials.gov Paclitaxel DRUG Phase PHASE2 Non-small Cell Lung Cancer ClinicalTrials.gov pemetrexed DRUG Phase PHASE2 Non-small Cell Lung Cancer ClinicalTrials.gov Carboplatin DRUG Phase PHASE2 Non-small Cell Lung Cancer ClinicalTrials.gov Tacrolimus DRUG Phase PHASE2 Primary Membranous Nephropathy ClinicalTrials.gov BGB-24714 DRUG Phase PHASE1 Solid Tumor, Adult ClinicalTrials.gov BGB-30813 DRUG Phase PHASE1 Advanced Solid Tumors ClinicalTrials.gov BG-C0902 DRUG Phase PHASE1 Solid Tumors ClinicalTrials.gov BGB-B455 DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov New Hormonal Agent DRUG Phase PHASE2 Prostate Cancer ClinicalTrials.gov Luteinizing Hormone Releasing Hormone DRUG Phase PHASE2 Prostate Cancer ClinicalTrials.gov Elacestrant DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov Letrozole DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov Phenytoin DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov Itraconazole DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov Drug: BG-T187 DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov BG-C137 DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov BGB-B3227 DRUG Phase PHASE1 Advanced Cancer ClinicalTrials.gov Pomalidomide DRUG Phase PHASE1 Relapsed/Refractory Multiple Myeloma ClinicalTrials.gov Daratumumab DRUG Phase PHASE1 Relapsed/Refractory Multiple Myeloma ClinicalTrials.gov Carfilzomib DRUG Phase PHASE1 Relapsed/Refractory Multiple Myeloma ClinicalTrials.gov Dexamethasone DRUG Phase PHASE1 Relapsed/Refractory Multiple Myeloma ClinicalTrials.gov Concurrent chemoradiotherapy (cCRT) DRUG Phase PHASE3 Carcinoma, Non-Small-Cell Lung ClinicalTrials.gov BGB-3111 DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov [14C]-BGB-3111 DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov BGB-3111 (Arm B) DRUG Phase PHASE1 Healthy Volunteers: Asian, Non-Asian ClinicalTrials.gov Rifampin DRUG Phase PHASE1 Healthy Volunteers: Asian, Non-Asian ClinicalTrials.gov BGB-3111 (Arm A) DRUG Phase PHASE1 Healthy Volunteers: Asian, Non-Asian ClinicalTrials.gov BGB-3111 and Drug Cocktail DRUG Phase PHASE1 Healthy Subjects ClinicalTrials.gov Moxifloxacin DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov BGB-B167 DRUG Phase PHASE1 Solid Tumors ClinicalTrials.gov Tislelizumab, AVD, Radiotherapy DRUG Phase PHASE2 Hodgkin Lymphoma ClinicalTrials.gov Hepatic arterial infusion chemotherapy PROCEDURE Phase PHASE1 Hepatocellular Carcinoma ClinicalTrials.gov Nocardia rubra cell wall skeleton DRUG Phase PHASE1 Hepatocellular Carcinoma ClinicalTrials.gov allo-HSCT PROCEDURE Phase PHASE2 Acute Myeloid Leukemia ClinicalTrials.gov Cytarabine DRUG Phase PHASE2 Acute Myeloid Leukemia ClinicalTrials.gov idarubicin/daunorubicin DRUG Phase PHASE2 Acute Myeloid Leukemia ClinicalTrials.gov Sorafenib DRUG Phase PHASE3 Hepatocellular Carcinoma (HCC) ClinicalTrials.gov Anlotinib DRUG Phase PHASE1 KRAS Mutation-Related Tumors ClinicalTrials.gov Trametinib DRUG Phase PHASE1 KRAS Mutation-Related Tumors ClinicalTrials.gov 💼 Business Developments: No business developments data available. Structured Data: Company Name: BeiGene LtdCIK: 0001651308Ticker Symbol: BGNEPeriod End Date: 2022-07-20Document Type: 8-K
📋 BEIGENE, LTD. (BGNE) - Regulatory Update
Filing Date: 2022-07-20
Accepted: 2022-07-20 17:07:05
Event Type: Regulatory Update
Event Details:
🔬 Clinical Development Pipeline (BEIGENE, LTD.):
💼 Business Developments:
No business developments data available.
Structured Data: